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Surface immobilization of bioactive molecules is a central paradigm in the design of
implantable devices and biosensors with improved clinical performance capabilities. However,
in vivo degradation or denaturation of surface constituents often limits the long-term per-
formance of bioactive ﬁlms. Here we demonstrate the capacity to repeatedly regenerate a
covalently immobilized monomolecular thin ﬁlm of bioactive molecules through a two-step
stripping and recharging cycle. Reversible transpeptidation by a laboratory evolved Staphy-
lococcus aureus sortase A (eSrtA) enabled the rapid immobilization of an anti-thrombogenic
ﬁlm in the presence of whole blood and permitted multiple cycles of ﬁlm regeneration in vitro
that preserved its biological activity. Moreover, eSrtA transpeptidation facilitated surface re-
engineering of medical devices in situ after in vivo implantation through removal and
restoration ﬁlm constituents. These studies establish a rapid, orthogonal and reversible
biochemical scheme to regenerate selective molecular constituents with the potential to
extend the lifetime of bioactive ﬁlms.
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M
edical devices in blood-contacting applications, such as
stents, heart valves, ventricular assist devices and
extracorporeal support systems, as well as vascular
grafts and access catheters are prone to failure due to maladaptive
host responses at the blood–material interface1–6. Immobilization
of bioactive molecules and drug eluting thin ﬁlms on implantable
devices have yielded promising combination products that
abrogate thrombotic cascades and detrimental inﬂammatory
reactions7–9, enhance device integration and local tissue
repair10 and inhibit microbial colonization11,12. However, the
clinical translation of these strategies remains constrained by the
limited therapeutic duration afforded by a ﬁnite reservoir of
bioactive agents, as well as by the degradation or denaturation of
surface components by oxidation, hydrolysis and proteolysis
when exposed over time to a physiological environment11,13–15.
Efforts to improve the stability and activity of thin ﬁlm
constituents for both biomedical and biotechnological
applications have included attempts to judiciously alter surface
properties, such as hydrophilicity, charge, topography16–18 and
immobilization chemistry19–22, as well as through rational and
evolutionary protein engineering23,24. Despite recent progress in
these areas, a surface coating for implantable devices that reliably
retains biological activity over extended clinically relevant
timescales has not been developed.
In principle, enzyme ligation offers an opportunity for
catalysing reversible bond-forming reactions that could enable
the molecular regeneration of bioactive thin ﬁlms in situ.
Staphylococcus aureus sortase A (SrtA) catalyses the covalent
transpeptidation of a C-terminal ‘sorting motif’ LPXTG to
N-terminal oligoglycine (for example, GGG) nucleophiles
through an acyl-enzyme complex forming an LPXT-GGG
bond25,26. Because of its synthetic simplicity and the very
limited occurrence of the LPXTG motif in native proteins,
SrtA-catalysed transpeptidation has been broadly applied in
protein puriﬁcation, labelling and immobilization onto solid
supports27–31. However, the low catalytic activity and substrate
afﬁnity of wild-type (WT) SrtA necessitates high molar excess of
the enzyme and long incubation times to approach reaction
completion, limiting its effectiveness and applicability. An
evolved SrtA mutant (eSrtA) has recently been generated that
exhibits 120-fold higher LPETG-ligation activity than the WT
enzyme30,32. This enzyme suggested the possibility of multiple
rapidly catalysed cycles of removal and reversible assembly of
bioactive molecular ﬁlms onto oligoglycine-modiﬁed surfaces
both in vitro and in vivo. Indeed, we observed that eSrtA
transpeptidation was reversible, enabling multiple cycles of
peptide bond formation and cleavage, and, thereby, facilitating
ﬁlm regeneration in the presence of whole blood in vitro and
in vivo. These studies establish a rapid, orthogonal and reversible
scheme, which can be used to regenerate selective molecular
constituents with the potential to extend the lifetime of bioactive
ﬁlms, or likewise, as a method to load and release any of a
number of material bound constituents for controlled drug
loading and delivery, or as a strategy for material dissolution.
Results
An evolved sortase catalyses rechargeable molecular assembly.
We have extensively characterized the ability of thrombomodulin
(TM) to limit tissue factor induced thrombin production under
venous and arterial ﬂow conditions using both experimental and
computational models31,33–38. Surfaces functionalized with TM, a
major physiological inhibitor of thrombin generation39,40, exhibit
reduced thrombogenicity in vitro and in vivo, thereby, supporting
its potential utility in blood-contacting devices31,37,41–49. To
demonstrate the ability to reversibly assemble TM on oligoglycine
surfaces in a site-speciﬁc manner (Fig. 1a), we ﬁrst generated a
recombinant human TM fragment containing a C-terminal
LPETG motif (TMLPETG). WT sortase (WT SrtA) and an eSrtA
produced by directed evolution using a yeast display system were
generated, as previously reported32. Model pentaglycine surfaces,
which match the natural SrtA substrate on the S. aureus cell
wall50 were constructed by immobilizing a biotinylated
pentaglycine peptide (NH2-GGGGGK-biotin) on surfaces pre-
coated with streptavidin. Surface immobilization of TMLPETG
using eSrtA yielded a B10-fold higher surface density than that
attained in the presence of an equivalent concentration of WT
SrtA. Further, despite a 20-fold increase in WT SrtA, only a
modest increase in TM surface density was observed (Fig. 1b).
Near-complete removal of immobilized TM ﬁlms could be
achieved with eSrtA in 30min, whereas WT SrtA was
substantially less efﬁcient under identical conditions (Fig. 1c).
In this system, the binding kinetics of TMLPETG by eSrtA roughly
approximated those of biotin-streptavidin (Fig. 1d). As illustrated
by 10 repetitive stripping and charging cycles using eSrtA, rapid
and reproducible regeneration of surface-bound TM ﬁlms proved
feasible with preservation of surface catalytic activity and
sustained production of activated protein C (aPC) (Fig. 1e,f).
TMLPETG-pentaglycine surfaces were incubated for up to 28 days
in Tris-buffered saline (TBS) at 37 C and subjected to three
cycles of stripping and recharging at 7-day intervals. We observed
no loss in efﬁciency of eSrtA stripping or recharging as
characterized by TM ELISA and TM co-factor activity over this
4-week period (Fig. 2a,b). These results conﬁrmed that the
enhanced catalytic activity of eSrtA is a critical enabling step in
the application of a two-step strip/recharge scheme for rapid and
repetitive regeneration of biologically active molecular ﬁlms.
Repetitive molecular recharging can be performed in blood.
Because of the rarity of LPETG and GGG motifs in native
proteins, we postulated that the two-step strip/recharge reaction
mediated by eSrtA would provide a feasible in vivo strategy to
selectively regenerate molecular constituents on or within medical
implants in situ. As proof-of-concept, we demonstrated the ability
to immobilize TMLPETG on pentaglycine surfaces in 50% v/v
whole blood at 37 C. We observed that eSrtA was capable of
efﬁciently functionalizing model surfaces greater than 20-fold
more effectively than WT SrtA (Fig. 3a). In addition, eSrtA was
capable of functionalizing surfaces in whole blood at levels
equivalent to that achieved in deﬁned reaction buffer with only a
ﬁve fold increased concentration (0.1 equivalents versus 0.5
equivalents). We performed repeated cycles of stripping/
recharging in 50% v/v whole blood and observed both efﬁcient
removal and regeneration of TM. Signiﬁcantly, aPC generation
after ﬁve rounds of charging was equivalent to that observed on
our initial model surface (Fig. 3b,c). These results underscore the
enhanced activity of eSrtA as an important enabling step towards
in situ assembly of molecular ﬁlms at the blood-contacting
interface of medical implants.
Sortase mediates molecular assembly and disassembly in vivo.
Polyurethane venous access catheters are widely used, but
continue to be limited by a risk of thrombosis and infection,
despite attempts to limit these risks by surface immobilization of
bioactive molecular ﬁlms51–55. As venous catheters are available
in sizes compatible for small animal studies, they provide a
convenient model system to assess stripping and recharging
of surface-bound biologically active molecules in vivo. Initial
investigations focused on the application of eSrtA trans-
peptidation to immobilize and remove LPETG-tagged probes
on pentaglycine-modiﬁed polyurethane catheters deployed in the
mouse inferior vena cava. Catheters were modiﬁed with
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cyclooctyne motifs using a sequential scheme (Supplementary
Fig. 1), as previously reported31,37, and azide reactivity was
conﬁrmed using rhodamine azide probes (Supplementary Fig. 2).
An azide-tagged pentaglycine peptide (NH2-GGGGG-N3) was
used to generate pentaglycine motifs on catheters. Reaction
parameters for eSrtA-mediated attachment and removal of a
biotin-LPETG probe on catheters were ﬁrst determined under
in vitro conditions (Supplementary Figs 3–5). Using 6–8-week-
old C57BL/6 mice, pentaglycine-modiﬁed catheters were inserted
via the femoral vein into the inferior vena cava, followed by
intravenous administration of eSrtA with either biotin-LPETG or
triglycine (GGG) to charge or strip the catheter surface,
respectively (Fig. 4a). Analysis of explanted catheters conﬁrmed
the selective immobilization or removal of biotin-LPETG probes
within 1 h (Fig. 4b,c and Supplementary Figs 6–9). In a parallel set
of experiments using catheters bearing Alexa Fluor 750-LPETG,
real-time ﬂuorescent imaging conﬁrmed that the surface-bound
near-IR probe was nearly completely removed within 1 h after
intravenous administration of eSrtA and GGG (Fig. 4d,e).
To determine whether nonspeciﬁc adsorption of plasma
proteins or other blood components limits surface accessibility
to systemically delivered eSrtA, catheters were deployed in the
jugular vein for 7 days using a rat model. Pentaglycine-derivatized
polyurethane catheters were inserted and after 1 week, Texas
Red-labelled TMLPETG was administered intravenously with or
without eSrtA. Catheters were explanted 1 h later and TM surface
conjugation was conﬁrmed using ﬂuorescence microscopy
(Fig. 5a and Supplementary Fig. 10). In situ stripping of Texas
Red-TMLPETG and recharging efﬁciency was examined in a
similar manner. Speciﬁcally, pentaglycine catheters functionalized
with Texas Red-TMLPETG were deployed within the jugular vein
for 7 days. Catheters were removed 1 h after intravenous
administration of GGG with or without eSrtA and stripping
veriﬁed by ﬂuorescence imaging (Fig. 5b and Supplementary
Fig. 10). In situ recharging was assessed by ﬁrst initiating the
in vivo removal of TMLPETG from catheter surfaces after
deployment within the rat jugular vein for 7 days, as detailed
above, followed 24 h later by intravenous administration of Texas
Red-TMLPETG with or without eSrtA. Signiﬁcantly, TM surfaces
could be charged, stripped and once again recharged with TM
to levels observed before catheter implantation (Fig. 5b,c and
Supplementary Fig. 10).
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Figure 1 | Sortase-catalysed rechargeable surface assembly. (a) Two-step ‘rechargeable’ surface assembly cycle initiated by sortase-catalysed charging
of LPETG-tagged biomolecules on pentaglycine-modiﬁed surfaces, followed by sortase-catalysed stripping to regenerate pentaglycine anchor sites for
additional surface reaction cycles. (b) Immobilization of 1mM TMLPETG on pentaglycine-coated microwells using 0.1 molar equivalents evolved sortase
(eSrtA), 0.1 and 2 molar equivalents WT SrtA, or no sortase as a negative control. (c) Following immobilization of 1 mM TMLPETG on pentaglycine-coated
microwells using 0.1 molar equivalents eSrtA, removal of bound TM was carried out using 20mM of either evolved eSrtA or WT SrtA with 1mM triglycine.
(d) Sortase-catalysed binding of TMLPETG on pentaglycine-modiﬁed model surfaces following 1 h and 16 h reactions were compared with the binding of
biotinylated TM (TM-biotin) directly on streptavidin-coated microwells. In parallel, TMLPETG was incubated in microwells without sortase as a negative
control. (e) Rapid repetitive recharging of TMLPETG on pentaglycine surfaces by eSrtA. Sequential eSrtA-catalysed charging (red) and stripping (blue) cycles
of TMLPETG on pentaglycine surfaces (n¼4). (f) Co-factor activity of immobilized TM to catalyse production of activated protein C (aPC) following the
initial assembly of TMLPETG, stripping by eSrtA, and regeneration of TMLPETG by eSrtA. **Po0.01, ***Po0.001 (Student’s t-test), error bars denote
s.d. (nZ3).
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Discussion
Current techniques to covalently modify surfaces with bioactive
compounds have largely involved bioconjugation schemes that
link nucleophilic motifs such as amines, thiols and hydroxyls to
respective partner electrophiles56. The abundant presentation of
these motifs in the complex chemical landscape of biological
systems reduces the efﬁciency of targeting payloads to regenerate
device reservoirs or surfaces. Recent efforts to modify blood-
contacting surfaces with bioactive molecules have led to the
application of a variety of bio-orthogonal coupling chemistries,
notably Staudinger ligation and native chemical ligation, as well
as click cycloaddition and intein-mediated splicing37,57–62.
However, these irreversible bond-forming approaches prohibit
the in situ removal and regeneration of surface assemblies.
Non-covalent strategies for recharging bioactive surfaces have
been proposed through the use of metal-afﬁnity63, N-halamine
structures64, disulﬁde bonds65 as well as through biotin–avidin
interactions66. Nonetheless, even under controlled in vitro
conditions, repetitive regeneration using these schemes is
challenging and would not be easily adaptable to surface
regeneration in vivo. eSrtA demonstrates promising utility for
the targeted regeneration of molecular constituents in vivo that
are bound on or potentially within a device. While eSrtA is a
bacterial protein and further studies to characterize its
immunogenicity are ongoing, precedent does exist for the
clinical use of bacterially sourced therapeutics, such as
streptokinase, uricase and asparaginase.
In this report, we demonstrate a site-speciﬁc covalent
immobilization of recombinant TM that has been speciﬁcally
engineered for enhanced protease stability and oxidation
resistance. We observed no decrease in surface-bound TM over
4 weeks in vitro; indeed, TM has been characterized with
remarkable stability and as such it is a promising candidate for
device functionalization. Despite the intrinsic stability of TM, we
anticipate the need to regenerate surface activity on permanent
blood-contacting prostheses with continuing efforts focused on
characterizing the bioactive half-life of surface-bound TM in vivo.
Importantly, we have determined that eSrtA permits the
engineering of covalently bound molecular assemblies onto
material surfaces that can be selectively and rapidly ‘recharged’
to sustain surface activity. In comparison with other chemoenzy-
matic approaches67–69, the enhanced kinetics and bond-forming
efﬁciency afforded by directed evolution of SrtA was a critical
enabling technology for this concept. We conﬁrmed the capacity
of eSrtA to catalyse multiple cycles of rapid assembly and removal
of LPETG-tagged biomolecules and established that such a
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Figure 2 | Repetitive surface assembly and removal over 28 days in vitro. (a) Sequential eSrtA-catalysed charging and stripping of TMLPETG
performed at 7-day intervals over a 28-day incubation. (b) aPC activity was conﬁrmed on initial surfaces and after three strip/charge events
performed on days 7, 14 and 28. N.S. (not signiﬁcant), error bars denote s.d. (nZ3).
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Figure 3 | Repetitive surface recharging in the presence of whole blood. (a) Direct sortase-catalysed assembly of TMLPETG in 50% v/v heparinized whole
blood (20U heparin per ml of blood) at 37 C for 1 h without additional calcium. Evolved and WT sortases were tested at two different TMLPETG
concentrations as well as TMLPETG/sortase ratios. (b) Sequential eSrtA-catalysed charging (red) and stripping (blue) cycles of TMLPETG performed
on model pentaglycine surfaces in 50% v/v heparinized whole blood (20U heparin per ml of blood) at 37 C for 1 h without additional calcium.
(c) TM co-factor activity (nM aPC/well) was characterized on initial surfaces and after the ﬁfth generation of charging. Blank wells were included
as control. N.S. (not signiﬁcant), *Po0.05, ***Po0.001 (Student’s t-test), error bars denote s.d. (nZ3).
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strategy could be performed in the presence of whole blood
in vitro and in vivo. Taken together, our ﬁndings establish
the capacity to rapidly and reproducibly regenerate selective
molecular constituents after device implantation with the
potential to substantially extend the lifetime of bioactive ﬁlms
and enhance clinically related performance characteristics. It is
anticipated that such a strategy could be applied to stripping and
regenerating any of a number of potential material bound
constituents that display ﬁnite stability or activity.
Methods
Materials. Unless otherwise speciﬁed, all reagents were purchased from Sigma-
Aldrich and used without further puriﬁcation. The peptides NH2-GGGGG-N3,
NH2-GGGGGK-biotin, biotin-LPETG and NH2-LPETG were obtained from
GenScript.
Synthesis of GGG-PEG5k-biotin. A total of 100mg of biotin-PEG(5k)-NH2
(Creative PEG works) and 32.3mg Fmoc-Gly-Gly-Gly-COOH (Santa Cruz
Biotechnology) were dissolved in 500 ml anhydrous dichloromethane. A total of
22.3mg of HBTU and 12.0mg of hydroxybenzotriazole were dissolved in 1ml of
anhydrous dimethylformamide. The resulting mixture was sonicated for 5min
before the addition of 13.7 ml of N,N-diisopropylethylamine and then reacted
overnight with stirring at room temperature. The mixture was quenched on ice by
the addition of 10 ml of triﬂuoroacetic acid and then precipitated by addition to
20ml of cold diethyl ether. The material was then ﬁltered, dried under reduced
pressure and subsequently dissolved in 1ml of 20% piperidine in dichloromethane
and incubated at room temperature for 30min to remove the Fmoc group.
The reaction was quenched by the addition of 0.2ml triﬂuoroacetic acid on ice,
precipitated with cold ethyl ether and recrystallized twice from cold isopropyl
alcohol. The precipitated sample was dissolved in 5ml of deionized water, dialyzed
(MWCO 2 kDa) against deionized water for 24 h, and then lyophilized.
Alexa Fluor 750-LPETG synthesis. A total of 25mg Alexa Fluor 750 NHS Ester
(Invitrogen) was dissolved in 45 ml of 0.4M NH2-LPETGG peptide in DMSO and
incubated at room temperature for 6 h. A total of 2.5 ml DIPEA was then added
and incubated at room temperature overnight. Reactions were quenched by the
addition of 450ml of 1M Tris, pH 7.5, which were incubated on ice for 2 h. The
reaction product was puriﬁed on a preparative Kromasil 100-5-C18 column
(21.2 250mm, Peeke Scientiﬁc) by reverse phase HPLC (ﬂow rate: 9.5mlmin 1;
gradient: 10–70% acetonitrile with 0.1% TFA in 0.1% aqueous TFA gradient
over 30min; retention time 8min) before pooling and lyophilizing the collected
fractions. The concentration of the peptide was determined by the known molar
extinction coefﬁcient of Alexa Fluor 750, e749nm¼ 290,000M 1 cm 1.
Expression of TMLPETG and sortase variants. Detailed DNA sequence, bacterial
expression and puriﬁcation of TMLPETG and sortase variants are provided in the
Supplementary Methods section (Supplementary Table 1). Met-388 was mutated to
Leu, which has been previously shown to result in a construct that is more resistant
to oxidative inactivation70.
Preparation of ﬂuorescently labelled TMLPETG. TM was modiﬁed with an
amine-reactive ﬂuorescent probe. A total of 4.0ml of TMLPETG stock in PBS
(1mgml 1) was prepared at 4 C and 100ml of Texas Red NHS ester (Invitrogen)
at 10mM in DMSO was added dropwise. The mixture was reacted for 1 h at room
temperature with stirring followed by an overnight incubation at 4 C. The solution
was then dialyzed against PBS at 4 C for 72 h to remove unreacted ﬂuorescent
dye and passed through a PD10 column with TBS buffer (25mM Tris, 150mM
NaCl, pH 7.5). The puriﬁed Texas Red-TM conjugate was analysed by UV–vis
spectroscopy and SDS–polyacrylamide gel electronphoresis performed by
illumination on a standard UV light box.
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Figure 4 | Sortase-catalysed reversible surface assembly in vivo. (a) Reversible assembly of LPETG-labelled probes (biotin-LPETG or Alexa Fluor 750-
LPETG) on pentaglycine-modiﬁed catheters deployed in vivo was achieved by intravenous delivery of eSrtA and triglycine peptide. (b) In situ eSrtA-
catalysed immobilization of LPETG-tagged biotin (biotin-LPETG) probes on pentaglycine-modiﬁed catheters in the mouse inferior vena cava, 1 h after
intravenous delivery of biotin-LPETG and eSrtA, catheters were explanted and incubated with Cy3-streptavidin to assess biotin surface density. (c) In situ
eSrtA-catalysed removal of LPETG-tagged biotin probes from pentaglycine-modiﬁed catheters deployed in the mouse inferior vena cava, 1 h after
intravenous delivery of triglycine (GGG) and eSrtA, catheters were explanted and incubated with Cy3-streptavidin to assess biotin surface density. (d) In
situ removal of LPETG-tagged near-IR probes from pentaglycine-modiﬁed PU catheters deployed in mouse vena cava. Representative real-time ﬂuorescent
imaging of a pentaglycine-modiﬁed polyurethane catheter functionalized with LPETG-labelled Alexa Fluor 750 deployed in the mouse vena cava and
stripped by intravenous delivery of eSrtA and triglycine. Catheters modiﬁed with pentaglycine peptide and conjugated with LPETG-labelled Alexa Fluor 750
were stripped by IV delivery of triglycine (400mg) and eSrtA (700mg). The near-IR ﬂuorescent signal from the modiﬁed catheter was monitored using the
Maestro multi-spectral ﬂuorescence imaging system in real time over 70min and (e) quantitative image analysis was performed to evaluate the
ﬂuorescent signal intensity of the modiﬁed catheters. ***Po0.001 (Student’s t-test), error bars denote s.d. (nZ3).
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Immobilization of TMLPETG on model substrates. Direct sortase-mediated
immobilization of TMLPETG on pentaglycine surfaces was tested in streptavidin-
coated 96-well microplates (Pierce). A total of 200mM NH2-GGGGG-biotin or
biotin-PEG5k-GGG was incubated for 1 h in each well, and washed with TBS
(20mM Tris, 100mM NaCl, pH 7.5) with 0.05% Tween 20. Various concentrations
of TMLPETG were immobilized using 0.1–2 molar equivalents of WT SrtA or eSrtA
for 1 h at room temperature. All sortase reactions were performed in a deﬁned
reaction buffer consisting of 25mM Tris-HCl, 150mM NaCl, 0.5mM CaCl2,
pH 7.5. Stripping of immobilized TM was performed using 20 mM SrtA and 1-mM
GGG peptide. SrtA-catalysed assembly of TMLPETG was performed in heparinized
(20Uml 1) whole blood, which was obtained from healthy volunteers under
approval of the BIDMC Institutional Review Board. Whole blood was diluted 50%
v/v with normal saline containing SrtA, TMLPETG, or GGG with reactions carried
out at 37 C for 1 h without additional calcium. As a reference binding reaction,
TMLPETG was biotinylated in a solution containing 100 molar equivalents of
NH2-GGGGG-biotin and 0.1 molar equivalents of eSrtA for 2 h to generate
TM-biotin, which was then incubated in streptavidin-coated microplates for
1 or 16 h. To examine eSrtA-mediated TMLPETG charging and stripping over a
28-day-incubation period, a GGG-functionalized substrate was generated by
incubating 200 ml of biotin-PEG5k-GGG for 2 h, followed by a wash in TBS with
0.05% Tween 20. TMLPETG was immobilized using 5mM TMLPETG and 0.5mM of
eSrtA for 1 h at room temperature in TBS. TM immobilized in 96 wells was washed
three times with TBS buffer with 0.5% Tween 20 and then incubated with
200ml of TBS buffer at 37 C for 7, 14, and 28 days. At designated time points,
sortase-mediated stripping and charging reactions were repeated over three cycles.
The quantity of TM immobilized in each well was determined by an ELISA
assay per manufacturer’s instructions (American Diagnostica). Surface activity of
immobilized TM was determined by incubating 100 ml of 0.2 mM human protein C
(Calbiochem, Gibbstown), 5mM calcium chloride and 2 nM human a-thrombin
(Haematologic Technologies) in Tris buffer (20mM Tris, 100mM NaCl, pH 7.5)
with 0.1% bovine serum albumin at 37 C for 1 h. Activated protein C generation
was determined using an enzymatically digestible chromogenic substrate
Spectrozyme PCa (Sekisui Diagostics). Experiments from three independent
replicates were averaged.
Modiﬁcation of catheters in vitro. Polyurethane catheters (1 Fr, 2 cm length, SAI
Infusion) were derivatized with pentaglycine motifs. For mouse studies, inner and
outer catheter surfaces were reacted with 16% v/v hexamethylene diisocyanate
(HDI) and 4% v/v triethylamine (TEA) in toluene for 1 h at 50 C and then rinsed
in toluene for 6 h. Isocyanate activated catheters were then reacted overnight at
40 C with 1mgml 1 dibenzocyclooctyne (DBCO)-amine linker (Click Chemistry
Tools) and TEA (1% v/v) in toluene, rinsed with toluene for 6 h, and dried
overnight under vacuum at 25 C. For rat studies, catheter lumens were heat sealed
before surface modiﬁcation and after isocyanate activation, as described above,
catheters were reacted overnight with 2mgml 1 DBCO-PEG2k-amine linker
(Nanocs) and TEA 1% v/v in acetonitrile at 40 C and then rinsed with acetonitrile
for 3 h. To conﬁrm surface cyclooctyne reactivity, DBCO-activated catheters were
reacted with 1mgml 1 tetramethyl-rhodamine-5-carbonyl azide (Invitrogen) in
1:4 tert-butanol/PBS at 37 C for 24 h followed by rinsing in methanol for 24 h.
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Figure 5 | In situ molecular recharging of venous catheters after in vivo deployment. (a) To characterize in situ charging of a chronically implanted venous
catheter, pentaglycine-modiﬁed polyurethane catheters were initially deployed in the rat jugular vein for 7 days. Texas Red-labelled TMLPETG with or without
eSrtA was systemically administered by intravenous injection via the dorsal penile vein. Catheters were removed 1 h later and imaged using ﬂuorescence
microscopy. Representative images are shown (scale bar, 1mm). (b) To characterize in situ stripping, pentaglycine catheters linked to Texas Red-TM were
deployed in the rat jugular vein for 7 days. GGG with or without eSrtA was delivered intravenously and 1 h later catheters were removed and imaged. To
examine in situ recharging, Texas Red-TM catheters were ﬁrst stripped by intravenous administration of GGG and eSrtA and 24 h later, Texas Red-TMLPETG
and eSrtA was administered intravenously. Catheters were removed 1 h later for imaging. Representative images are shown (scale bar, 1mm). (c) Catheter
ﬂuorescence intensity was quantiﬁed using ImageJ and plotted as. *Po0.05, **Po0.01, ***Po0.001 (Student’s t-test), error bars denote s.d. (nZ3). A.U.,
arbitrary units.
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DBCO activated catheters were reacted overnight with NH2-GGGGG-N3 at 37 C
and rinsed with TBS buffer. Pentaglycine-modiﬁed catheters were incubated with
biotin-LPETG or LPETG-labelled Alexa Fluor 750 peptide (2 to 100 mM) and 0.1
molar equivalents of eSrtA relative to the LPETG probe concentration for 30min
or 1 h and rinsed for 4 h in TBS. Biotinylated catheters were incubated in
0.1mgml 1 Cy3-labelled streptavidin in TBS with 0.05% Tween 20 for 30min and
rinsed overnight in TBS. Imaging of catheters was carried out using the Zeiss
Discovery V20 Stereo Microscope and quantitative image analysis by ImageJ was
performed to determine ﬂuorescence intensity.
In situ modiﬁcation of catheters deployed in mice. All animal studies were
conducted under the approval of the BIDMC Animal Care and Use Committee.
Pentaglycine-modiﬁed catheters were deployed B1 cm within the inferior vena
cava via the femoral vein in 6–8-week-old C57BL/6 mice. All animals were
maintained under anaesthesia with isoﬂurane or ketamine on a heating pad. To
functionalize pentaglycine-modiﬁed catheters in situ, a 200 ml solution containing
4 nmol eSrtA, 40 nmol LPETG-tagged biotin and 20U of heparin was administered
intravenously through the catheter inlet followed by a 100ml saline ﬂush. To
demonstrate in situ removal of LPETG-tagged biotin probes from pentaglycine-
modiﬁed catheters, a 200ml solution containing 40 nmol eSrtA, 2 mmol GGG
peptide and 20U of heparin was injected intravenously through the catheter inlet
followed by a 100 ml saline ﬂush. Mice were sacriﬁced 1 h later and catheters were
explanted and incubated in streptavidin-Cy3 (30min) and washed with TBS buffer
(2 h). Fluorescent and bright ﬁeld microscopy images were obtained to detect
biotin groups on the catheter surface. Real-time imaging of in situ removal of
LPETG-tagged Alexa Fluor 750 was performed using a Maestro Multi-Spectral
in vivo ﬂuorescence imaging system with near-IR ﬁlter sets. Images were taken
using a monochromatic 12-bit camera and analysed using ImageJ to determine
ﬂuorescence intensity.
In situ modiﬁcation of catheters deployed in rats. DBCO-activated PU catheters
were generated as described above, reacted overnight with NH2-GGGGG-N3 at
37 C, and rinsed in TBS buffer. Free cyclooctyne groups were blocked with
2-azidoethanol (25mM) in TBS at RT for 1 h and catheters then rinsed with TBS
overnight in the dark. Pentaglycine catheters were subsequently reacted with 10 mM
Texas Red-TMLPETG and 1 mM eSrtA for 1 h at 37 C. Under anaesthesia,
pentaglycine or Texas Red-TM catheters were deployed within the external jugular
vein of Wistar rats (75–100 g, male). The external end of the catheter was trimmed
and tucked into the subcutaneous soft tissue and held in place with a suture.
Catheters were maintained in vivo without administration of a systemic
anti-coagulant or anti-platelet agent. Seven days after catheter implantation,
rats were anaesthetized and ‘stripping’ or ‘charging’ reagents were delivered
intravenously via the dorsal penile vein (n¼ 5/test group). To charge pentaglycine
catheters, 80 nmol Texas Red-TMLPTEG with or without 8 nmol eSrtA was delivered
(400 ml, saline). To strip catheters, 8 mmol GGG with or without 160 nmol eSrtA
was delivered (400 ml, saline). For recharging experiments, catheters were stripped
in vivo and 24 h later, rats were anaesthetized and charging agents delivered
intravenously. Reagents were allowed to circulate for 1 h before catheter removal
and imaging by ﬂuorescence microscopy (Axio Zoom, Zeiss). Fluorescent intensity
was quantiﬁed using Image J64. Catheters displayed no sign of adherent thrombus
upon removal (Supplementary Fig. 11).
Statistical Analysis. Mean and s.d. were calculated for each parameter. Tests for
signiﬁcance between two groups were conducted with the Student’s t-test. Tests
between three or more groups were conducted with analysis of variance. Values of
Po0.05 were considered statistically signiﬁcant.
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